{
}
Retirement Wealth Solutions LLC and Marquette Asset Management LLC recently acquired new positions in AbbVie, valued at approximately $35,000 and $39,000, respectively. Mizuho Securities doubled its stake, now holding 200 shares worth $39,000. Institutional investors own 70.23% of AbbVie, which develops and sells pharmaceuticals like Humira and Skyrizi. Analysts have mixed ratings on the stock, with a consensus "Moderate Buy" and a price target averaging $207.55. AbbVie reported earnings of $2.16 per share, missing estimates, and has a market cap of $333.59 billion.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Novartis and AbbVie secured a legal victory against West Virginia's S.B. 325, which mandated drugmakers to distribute discounted drugs to unlimited pharmacies under the 340B Drug Pricing Program. The court found that the law obstructs federal objectives and imposes irreparable harm on the pharmaceutical industry, blocking its enforcement while the case proceeds. The ruling highlights the law's conflict with federal regulations, particularly regarding audits and penalties for non-compliance.
The consumer healthcare market is projected to grow significantly, reaching $1,476.45 billion by 2028, with a CAGR of 22.1%. Key drivers include an aging population, increased reliance on OTC medications, and the rise of e-commerce. Major players like Johnson & Johnson and Sanofi are adapting to trends in digital health and personalized care solutions.
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
Analysts made significant calls on various companies, with Goldman Sachs initiating coverage of Flutter and Aecom as buys, citing strong market positions. Citi reiterated a buy on Apple, predicting a successful holiday season for iPhones, while Needham expressed optimism for Nike under new leadership. Other notable mentions include upgrades for KinderCare and Bright Horizons, and a downgrade for Nvidia based on valuation concerns.
The endometriosis treatment market is projected to grow from USD 1.4 billion in 2023 to USD 3.1 billion by 2034, driven by increasing awareness and advancements in treatment options. Key trends include the rise of non-hormonal therapies and personalized medicine, while challenges such as high costs and limited access persist, particularly in developing regions. The competitive landscape features major players like AbbVie and Pfizer, alongside emerging companies innovating to meet unmet needs.
Pharmaceutical companies are increasingly focusing on access to medicines in low-income countries, with Novartis leading the way by integrating access plans into 96% of its late-stage drug projects. However, many companies still prioritize the US market, resulting in limited availability of essential medicines globally. Roche aims to double patient treatment numbers in low-income regions by 2026, yet significant gaps in transparency and patient reach persist across the industry.
The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.
The global market for synthetic lethality drugs and targets is projected to grow from $1.3 billion in 2023 to over $5.3 billion by 2033, with a CAGR of 15.09%. North America is expected to dominate the market due to advances in genetic science and rising cancer rates, while the Asia-Pacific region is anticipated to experience the fastest growth. Key players include Pfizer, AbbVie, and AstraZeneca, with increasing investments in biotechnology and personalized medicine driving innovation in cancer treatment.
AbbVie Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
abbVie sees increased institutional interest and mixed analyst ratings
17:38 03.02.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
court blocks west virginia law limiting drug distribution under 340b program
18:01 18.12.2024
consumer healthcare market poised for rapid growth driven by digital innovations
United States Dollar
Perrigo Company plc
Cardinal Health, Inc.
Johnson & Johnson
Church & Dwight Co., Inc.
Herbalife Nutrition Ltd.
Nestlé S.A.
Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
AstraZeneca PLC
DSM Nutritional Products AG
Pfizer Inc.
Colgate-Palmolive Company
AbbVie Inc.
Bayer AG
BASF SE
Glaxosmithkline plc
Novartis International AG
CVS Health Corporation
Boehringer Ingelheim International GmbH
Sanofi
Amway Corporation
Novo Nordisk A/S
Ipsen S.A.
Bristol-Myers Squibb Company
McKesson Corporation
Merck & Co., Inc.
The Clorox Company
Reckitt Benckiser Group plc
Cigna Corporation
Eli Lilly and Company
Brian Johnson
Show more
00:30 27.11.2024
rth america oncology drugs market projected to reach 27.20 billion by 2033
United States Dollar
Novartis AG
Gilead Sciences, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Amgen Inc.
Bristol-Myers Squibb Company
Biogen Inc.
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Celgene Corporation
AbbVie Inc.
Eli Lilly and Company
USA
Show more
14:29 22.11.2024
analysts issue major stock ratings for key companies including apple and nvidia
NXP Semiconductors N.V.
Apple Inc.
Microsoft Corporation
Amazon.com, Inc.
Global Business Travel Group, Inc.
Elastic N.V.
Kyndryl Holdings, Inc.
NIKE, Inc.
Arm
AbbVie Inc.
NVIDIA Corporation
USA
GBR
Elliott Hill
John Donohoe
Show more
14:25 22.11.2024
endometriosis treatment market projected to reach 3.1 billion by 2034
United States Dollar
AstraZeneca PLC
AbbVie Inc.
Bayer AG
Johnson & Johnson
Pfizer Inc.
USA
DEU
AbbVie Inc.
Bayer AG
AstraZeneca
Johnson & Johnson
Pfizer Inc.
Show more
16:12 19.11.2024
pharmaceutical industry struggles to improve access to medicine in low-income countries
Bristol-Myers Squibb Company
GSK plc
Hoffmann-La Roche AG
AbbVie Inc.
Sanofi
Novo Nordisk A/S
Novartis AG
Johnson & Johnson
Pfizer Inc.
GBR
CHE
NLD
Jayasree Iyer
Sabastine Wakdok
Show more
14:30 19.11.2024
global hashimoto thyroiditis market projected to reach 12.6 billion by 2033
United States Dollar
Amgen Inc.
Merck & Co., Inc.
Novartis AG
Sanofi
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Takeda Pharmaceuticals Limited Company
Bayer AG
Pfizer Inc.
Roche Holding AG
AbbVie Inc.
AstraZeneca PLC
Eli Lilly and Company
Glaxosmithkline plc
ARG
GBR
FRA
ITA
KOR
ZAF
MEX
USA
BRA
ESP
SAU
CAN
QAT
ARE
JPN
AUS
DEU
CHN
RUS
IND
Pfizer Inc.
AbbVie Inc.
Mylan N.V.
Inc.
Merck & Co
GlaxoSmithKline plc
Show more
04:38 19.11.2024
ynthetic lethality drugs market projected to reach 5.3 billion by 2033
GlaxoSmithKline
AbbVie Inc.
Pfizer Inc.
AstraZeneca
CAN
GBR
FRA
ARE
ITA
JPN
KOR
DEU
MEX
CHN
ZAF
USA
BRA
ESP
IND
Show more
03:52 19.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Finance Mergers & Acquisitions
Industry Trends
Hedge Funds & Private Equity
Global Financial Events
Global Trade Developments
Market Analysis and Predictions
Financial Scams and Security
Government Policies
Banking Regulations
Economic Sanctions
CEO Changes
Retail and Consumer Goods
Startups & Entrepreneurship
Industry Mergers & Acquisitions
International Relations
Central Bank Actions
Workplace Trends
Domestic Politics
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
The Goldman Sachs Group, Inc.
Wells Fargo & Company
Bank of America Corporation
Barclays PLC
Apple Inc.
Morgan Stanley
Citigroup Inc.
Berkshire Hathaway Inc.
Microsoft Corporation
SpaceXCoin USD
The Charles Schwab Corporation
AMERICAN EXPRESS
Amazon.com, Inc.
U.S. Bancorp
UBS Group AG
Banco Santander, S.A.
Deutsche Bank Money Market PP
Citizens, Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
British Pound Sterling
South Korean Won
Swiss Franc
United Arab Emirates Dirham
Canadian Dollar
Israeli New Shekel
Swedish Krona
Mexican Peso
New Taiwan Dollar
People: